TrialHypertension (Dallas, Tex. : 1979)2020

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.

Pierre Verweij et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.